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Background: Phenylazonaphtol-β-D-O-glycosides are alternative substrates for the detection of enzymatic activity of
β-glycosidases which are involved in various important processes. These azoic compounds are currently exploited
as prodrugs for colonic disease due the presence of β-glycosidase activity in the gut flora and therefore allowing
the release of the drug at the specific site.
Results: Phenylazonaphtol-β-D-O-glucoside 3a and galactoside 3b were prepared via diazonium salt conditions
under weak acidic conditions which do not compromise the O-glycosidic bond stability, by coupling reaction
between 2-naphtol sodium salt with aminoglycosides 1a and 1b. The resulting phenylazonaphtol glycosides 2a and
2b were deprotected affording the phenylazonaphtol glycosides 3a and 3b in quantitative yield. The galactoside
glycoside 3b was assayed as substrate for in vitro β-galactosidase enzymatic activity showing strong absorbance
after releasing of the azoic chromophore. Also, docking studies were performed to determine the best pose as well
as the interactions between the ligand and the residues located at the active site.
Conclusions: The methodology developed for synthesizing the phenylazonaphtol glycosides described proved to
be convenient for generating azoic functionalities in the presence of glycosidic bonds and the glycosides suitable
as alternative substrates and potentially useful prodrugs in the treatment of colonic diseases.
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β-glycosidases are hydrolytic enzymes involved in a num-
ber of important processes such as defense mechanism,
growth regulation [1], gene markers in transgenic plants
[2], and prodrugs [3]. The most commonly used substrates
for the histochemical localization of β-glycosidases con-
tain the 5-bromo-4-chloro-3-indolyl chromophore at-
tached to most of the known monosaccharides through
an O-glycosidic bond [4]. After enzymatic hydrolysis, the
water soluble indoxyl intermediate must undergo an oxi-
dative dimerization to produce a blue precipitate. How-
ever, in some cases before dimerization occurs to produce
the indigo dye, some diffusion takes place, producing false* Correspondence: mbrito@ipn.mx
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in any medium, provided the original work is ppositives at some regions in cells lacking enzymatic activ-
ity [5]. In addition, phenylazonaphtol glucosides have been
synthetically prepared and tested in transgenic plants con-
taining the β-glucuronidase activity which is a widely used
gene marker. A comparative test between the commer-
cially available glycosidic indoxyl substrates with the alter-
native phenylazonaphtol glucuronides resulted in partial
diffusion for the indigo dye and no detectable diffusion for
the phenylazonaphtol chromophore [6,7].
On the other hand, glycosides when attached to pharma-
cologically active substances can be used as prodrugs for
improving availability, stability, and particularly for specific
delivery of the active compound at the target organ. For
instance, steroids, antitumor, and anti-inflammatory com-
pounds have been attached to glycosides and evaluated as
specific delivery prodrugs [8]. Also, azoic β-glycosides pro-
vided to be useful as prodrugs particularly against colitis,is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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at colon level might be achieved by the action of azo-
reductase or glycosidase present at the colonic micro-
flora [9].
Due the potential usefulness of phenylazonaphtol gly-
cosides in processes mentioned above, we developed a
methodology for preparing phenylazonaphtol glycosides
under weak acidic conditions and the resulting azoic gly-
cosides evaluated as β-galactosidase substrates with po-
tential application as prodrugs for colon diseases.
Methods
The preparation of the phenylazonaphtol glycosides 3a
and 3b was achieved according to Scheme 1 consisting
in the coupling reaction between 2-naphtol in the so-
dium salt form with 4-aminophenyl tetracetyl glycopyra-
noside [10-12] 1a and 1b under modified diazonium salt
condition, which is mainly the use of acetic acid instead
of stronger acids, with sodium nitrite at 0°C to produce
the diazonium salts which was condensed in situ with 2-
naphtol sodium salt providing the corresponding pheny-
lazonaphtol tetracetyl glucopyranoside 2a and 2b. Final
removal of the acetate protecting groups under Zemplen
conditions provided the target phenylazonaphtol glyco-
sides 3a and 3b as a reddish solid in 60% yield.
Scheme
The beta galactosidase assay. β-galactosidase (2 mg; 2.1 U/
mg) was suspended in 0.8 mL of buffer containing 0.06 M








1a ; R1 =  OAc, R2 = H, R3 = Ac











3a ; R1 =  OH, R2 = H
3b ; R1 =  H, R2 = OH
Scheme 1 The preparation of the phenylazonaphtol glycosides 3a anand 1 mM DTT, pH 7.0, and then incubated with glycoside
3b (4 mg; 9.3 × 10−3 mM) in a mixture of 50 mM acetate
buffer with pH 5.0 (0.5 mL) and methanol (0.5 mL) at 37°C
for 3 h. The reaction was stopped by adding 0.5 mL 1 M
Na2CO3. The amount of the released phenylazonaphtol
chromophore was measured spectrophotometrically at 410
and 455 nm [13].
Results and discussion
The deprotected glycoside 3b was tested as substrate for
the detection of glycosidase activity using commercial
Escherichia coli β-galactosidase. Thus, the hydrolytic ac-
tivity resulted in the cleavage of the glycosidic linkage, re-
leasing the phenylazonaphtol chromophore which is
observed as an intense reddish color with absorption at
410 and 455 nm, as it is observed in the absorption
graphic (Figure 1) and as observed in the vials (Figure 2).
Docking studies
The active site architecture showing the interactions be-
tween the phenylazonaphtol galactoside 3b and E. coli β-
galactosidase pocket was performed using AutoDock 4.2
[14] and Chimera [15] software packages as visualization
system. The protein assigned for the docking analysis
was E. coli β-galactosidase (PDB IDs: 1JYN), and the resi-
dues chosen were Asn102, Asp201, Asn460, His418,
Glu461, Glu537, His540, Phe 601, and Trp999 which have
been described to participate in the interactions with its
natural substrate lactose [16]. β-galactosidase is a retaining
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Figure 1 Adsorption of 3b without β-galactosidase (1) and with β-galactosidase (2).
Figure 2 Vials containing 3b without β-galactosidase (less colored)
and 3b incubated with β-galactosidase.
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of water and the ions Mg2+ and Na1+ within the catalytic
cavity [17]. The docking analysis was performed to find
the minimized conformations according to the docking
protocols which use the Lamarckian Genetic Algorithm
for searching the most favorable ligand-protein complex
interactions. Thus, as a result of the docking analysis, we
found the minimized conformer with the galactose moiety
positioned toward the active site having a binding energy
of −11.62, showing hydrogen bond interactions of C-3 and
C-4 hydroxyl groups of galactoside moiety with Glu461
residue, in agreement with those reported for the natural
substrate lactose [16] (Figure 3).
The ribbon representation was also analyzed by using
the chimera visualizing system to show the region of the
cavity and the residues involved in the interaction with
the substrate 3b (Figure 4).
In addition, the surface representation shows that the
galactopyranoside moiety is embedded into the pocket
interacting with the residues while the azoic chromophore
Figure 3 The first scored conformation assumed by 3b presenting hydrogen bond interactions with Glu461 residue.
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Figure 5.
Experimental
All the reagents were purchased from Aldrich Chem-
ical Co. (St. Louis, MO, USA) except HBr/acetic acid
which was purchased from Fluka Chemical Co. (Buchs,
Switzerland). Column chromatography was performed on
silica gel with a 70-230 mesh, and thin-layer chromatog-
raphy on Kieselgel, both from Merck Co. (Darmstadt,
Germany), which was used as a detection system. A cer-
ium sulfate solution followed by heating on hot plate.
Infrared (IR) spectra were obtained on Perkin-Elmer
spectrometer (Waltham, MA, USA); nuclear magnetic
resonance (NMR) spectra were recorded on Varian 300-
MHz spectrometer (Palo Alto, CA, USA) and Bruker
500 MHz (Karlsruhe, Germany). Mass spectrum (MS)
spectra were obtained using a Hewlett-Packard 5989A
(Palo Alto, CA, USA). Optical rotations were measuredFigure 4 Ribbon representation. This shows the region of the active site
ligand.with a Perkin-Elmer 341 polarimeter at 23°C. Enzyme
galactosidase was purchased from Sigma Chemical
Company (St. Louis, MO, USA).
1-[(4-tetra-O-acetyl-β-D-glucopyranosyloxy phenyl)azo]-2-
naphtol (2a)
Compound 1a (0.543 g, 1.23 mmol) was dissolved in 8 mL
of THF, and the flask was cooled to 0°C. After the addition
of sodium nitrite (85 mg, 1.23 mmol) and 0.5 mL of acetic
acid/H2O (1:1, v/v), the reaction was kept under ice-bath
temperature with stirring for 15 min. 2-naphtol sodium
salt dissolved in 5 mL of THF/H2O (1:1, v/v) was added
dropwise in another flask, and the reaction was kept at
0°C with stirring for 30 min, allowing the reaction to reach
room temperature and stirred for another 60 min. The
solvent was removed under vacuo, diluted with CH2Cl2
(30 mL) and washed with cold 2 N NaOH solution (3 ×
15 mL) and water (20 mL). The organic phase was dried
over anhydrous sodium sulfate and evaporated onamong the protein and residues involved in the interaction with the
Figure 5 Surface representation showing the pose of ligand 3b at the active.
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raphy with AcOEt/hexane (1:3) to give an orange-red solid
(325 mg, 60%). m.p. 81°C to 83°C, [α]D −13.1 (c 0.6,
CHCl3), IR (thin film) 1,738 cm
−1, 1H NMR (CDCl3) δ
2.05 to 2.14 (4 s, 12 H), 3.92 (m, H-5), 4.20 (dd, H-6, J =
12.3 Hz, 2.1 Hz), 4.33 (dd, H-6′, J = 12.3 Hz, 5.1 Hz), 5.17
(d, H-1, J = 7.5 Hz), 5.20 (t, H-4, J = 9.6 Hz), 5.31 (t, H-2,
J = 9.6 Hz), 5.34 (t, H-3, J = 9.6 Hz), 6.97 (d, H-13, J = 9.3),
7.15 (d, H-8, 8′, J = 5.1 Hz), 7.41 (t, H-16, J = 7.5 Hz,
7.2 Hz), 7.58 (t, H-17, J = 7.5 Hz, 7.2 Hz), 7.66 (d, H-15,Figure 6 Structure of 1-[(4-tetra-O-acetyl-β-D-glucopyranosyloxy phenJ = 8.1 Hz), 7.75 (d, H-14, J = 9.6 Hz), 7.76 (d, H-9,9′, J =
9.0 Hz), 8.62 (d, H-18, J = 7.8 Hz). 13C NMR (CDCl3) δ
20.5, 20.6 (4 CH3-), 61.8 (C-6), 68.1 (C-4), 71.1 (C-3), 72.1
(C-2), 72.6 (C-5), 98.9 (C-1), 117.8 (C-8), 121.0 (C-9),
121.5 (C-18), 123.0 (C-13), 125.2 (C-16), 127.7 (C-14a),
128.1 (C-11), 128.4 (C-17), 129.7 (C-15), 133.3 (C-18a),
138.2 (C-10), 142.6 (C-14), 156.8 (C-7), 165.1 (C-12),
169.2, 169.3, 170.1, 170.4 (4 C = O). HRMS calculated

































3a ; R1 =  OH, R2 = H, R3 = H
3b ; R1 =  H, R2 = OH, R3 = H
Figure 7 Structure of 1-[(4-β-D-glucopyranosyloxy
phenyl)azo]-2-naphtol (3a).
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azo]-2-naphtol (2b)
Same reaction conditions as for 2a except that com-
pound 1b is used instead of 1a.
1H NMR (CDCl3) δ 2.09 to 2.12 (4 s, 12 H), 4.12 (1H,
m, H-5), 4.22 (1H, dd, H-6), 4.26 (1-H, dd, H6′), 5.11
(1H, d, H-1), 5.13 (1H, dd, H-4), 5.48 (1H, t, H-2), 5.54
(1H, dd, H-3), 6.97 (d, H-13, J = 9.3), 7.15 (d, H-8, 8′, J =
5.1 Hz), 7.41 (t, H-16, J = 7.5 Hz, 7.2 Hz), 7.58 (t, H-17,
J = 7.5 Hz, 7.2 Hz), 7.66 (d, H-15, J = 8.1 Hz), 7.75 (d, H-
14, J = 9.6 Hz), 7.76 (d, H-9,9′, J = 9.0 Hz), 8.62 (d, H-18,
J = 7.8 Hz). 13C NMR (CDCl3) δ 20.8, 20.9 (4 CH3-), 61.5
(C-6), 67.0 (C-4), 68.7 (C-2), 71.2 (C-3), 71.4 (C-5), 99.7
(C-1), 117.8 (C-8), 121.0 (C-9), 121.5 (C-18), 123.0 (C-13),
125.2 (C-16), 127.7 (C-14a), 128.1 (C-11), 128.4 (C-17),
129.7 (C-15), 133.3 (C-18a), 138.2 (C-10), 142.6 (C-14),
156.8 (C-7), 165.1 (C-12), 169.2, 169.3, 170.1, 170.4 (4 C =
O). MS (EI) m/z 594.18 [M+], 169 (100), 264 (62).1-[(4-β-D-glucopyranosyloxy phenyl)azo]-2-naphtol (3a)
To protected phenylazonaphtol glycoside 2a (0.3 g,
0.504 mmol), 5 mL of 10% NaOMe in MeOH was added
and stirred in a room temperature for 2 h. Ion exchange
resin Dowex 50WX2-100 was added to neutralize and the
resin filtered. The solvent was removed under vacuo to
give 0.193 g, 90% as a red solid (Figure 7).
m.p. 177°C to 178°C, [α]D −23.4 (c 0.9, MeOH), 1H
NMR (DMSO d-6) δ 3.13 (H-2), 3.30 (H-4), 3.35 (H-5),
3.37 (H-3), 3.60 (H-6), 3.75 (H-6′), 4.99 (H-1, J = 7.8),
6.97 (d, H-13, J = 9.3), 7.15 (d, H-8, 8′, J = 5.1 Hz), 7.41
(t, H-16, J = 7.5 Hz, 7.2 Hz), 7.58 (t, H-17, J = 7.5 Hz,
7.2 Hz), 7.66 (d, H-15, J = 8.1 Hz), 7.75 (d, H-14, J =
9.6 Hz), 7.76 (d, H-9,9′, J = 9.0 Hz), 8.62 (d, H-18, J =
7.8 Hz). 13C NMR (DMSO d-6) δ 61.7 (C-6), 76.8 (C-5),
71.6 (C-4), 74.1 (C-2), 76.7 (C-3), 96.7 (C-1), 117.8 (C-8),121.0 (C-9), 121.5 (C-18), 123.0 (C-13), 125.2 (C-16),
127.7 (C-14a), 128.1 (C-11), 128.4 (C-17), 129.7 (C-15),
133.3 (C-18a), 138.2 (C-10), 142.6 (C-14), 156.8 (C-7),
165.1 (C-12), 169.2, 169.3, 170.1, 170.4 (4 C =O). HRMS
calculated for C22H22N2O7 (M +H) 427.1505, found
427.1509.
1-[(4-β-D-galactopyranosyloxy phenyl)azo]-2-naphtol (3b)
Same reaction conditions as for 3a except that com-
pound 2b is used instead of 2a. 1H NMR (DMSO d-6) δ
3.41 (t, H-2), 3.56 (dd, H-3), 3.61 (m, H-5), 3.62 (H-6),
3.70 (H-6′), 3.84 (dd, H-4), 4.98 (d, H-1, J = 8.0), 6.97 (d,
H-13, J = 9.3), 7.15 (d, H-8, 8′, J = 5.1 Hz), 7.41 (t, H-16,
J = 7.5 Hz, 7.2 Hz), 7.58 (t, H-17, J = 7.5 Hz, 7.2 Hz), 7.66
(d, H-15, J = 8.1 Hz), 7.75 (d, H-14, J = 9.6 Hz), 7.76 (d,
H-9,9′, J = 9.0 Hz), 8.62 (d, H-18, J = 7.8 Hz). 13C NMR
(DMSO d-6) δ 62.0 (C-6), 69.7 (C-4), 72.9 (C-2), 73.8
(C-3), 76.0 (C-5), 97.3 (C-1), 117.8 (C-8), 121.0 (C-9),
121.5 (C-18), 123.0 (C-13), 125.2 (C-16), 127.7 (C-14a),
128.1 (C-11), 128.4 (C-17), 129.7 (C-15), 133.3 (C-18a),
138.2 (C-10), 142.6 (C-14), 156.8 (C-7), 165.1 (C-12),
169.2, 169.3, 170.1, 170.4 (4 C =O). FABMS (M + 1)
427.1.
The Additional file 1 (as word document) shows the
1H, 13C NMR spectra for the synthesized compounds
2a-b and 3a-b, and high-resolution mass spectrometry
and elemental analysis are also included.
Conclusions
The methodology developed for synthesizing the pheny-
lazonaphtol glycosides described proved to be conveni-
ent for generating azoic functionalities in the presence
of glycosidic bonds, and the glycosides are suitable as al-
ternative substrates and potentially useful prodrugs in
the treatment of colonic diseases.
Additional file
Additional file 1: Bidimensional NMR spectroscopy for compound
2a. Homonuclear through-bond correlation bidimensional spectroscopy
(COSY), heteronuclear single quantum coherence (HSQC), and heteronuclear
multiple bond correlation (HMBC) experiments are included to provide
further evidence for compound 2a.
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